Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Commercial

Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk

 April 9, 2026

BioPharma Dive

After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.

CommercialMetabolic & GLP-1Read full story

Post navigation

Pulmonary fibrosis drug developer Avalyn files IPO →
← Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com